Literature DB >> 30045977

LRRK2 activation in idiopathic Parkinson's disease.

Roberto Di Maio1,2,3, Eric K Hoffman1,2, Emily M Rocha1,2, Matthew T Keeney1,2, Laurie H Sanders1,2,4, Briana R De Miranda1,2, Alevtina Zharikov1,2, Amber Van Laar1,2, Antonia F Stepan5, Thomas A Lanz5, Julia K Kofler6, Edward A Burton1,2,7, Dario R Alessi8, Teresa G Hastings1,2, J Timothy Greenamyre9,2,7.   

Abstract

Missense mutations in leucine-rich repeat kinase 2 (LRRK2) cause familial Parkinson's disease (PD). However, a potential role of wild-type LRRK2 in idiopathic PD (iPD) remains unclear. Here, we developed proximity ligation assays to assess Ser1292 phosphorylation of LRRK2 and, separately, the dissociation of 14-3-3 proteins from LRRK2. Using these proximity ligation assays, we show that wild-type LRRK2 kinase activity was selectively enhanced in substantia nigra dopamine neurons in postmortem brain tissue from patients with iPD and in two different rat models of the disease. We show that this occurred through an oxidative mechanism, resulting in phosphorylation of the LRRK2 substrate Rab10 and other downstream consequences including abnormalities in mitochondrial protein import and lysosomal function. Our study suggests that, independent of mutations, wild-type LRRK2 plays a role in iPD. LRRK2 kinase inhibitors may therefore be useful for treating patients with iPD who do not carry LRRK2 mutations.
Copyright © 2018 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30045977      PMCID: PMC6344941          DOI: 10.1126/scitranslmed.aar5429

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   17.956


  37 in total

1.  Intersecting pathways to neurodegeneration in Parkinson's disease: effects of the pesticide rotenone on DJ-1, alpha-synuclein, and the ubiquitin-proteasome system.

Authors:  Ranjita Betarbet; Rosa M Canet-Aviles; Todd B Sherer; Pier G Mastroberardino; Chris McLendon; Jin-Ho Kim; Serena Lund; Hye-Mee Na; Georgia Taylor; Neil F Bence; Ron Kopito; Byoung Boo Seo; Takao Yagi; Akemi Yagi; Gary Klinefelter; Mark R Cookson; J Timothy Greenamyre
Journal:  Neurobiol Dis       Date:  2006-01-24       Impact factor: 5.996

2.  Leucine-rich Repeat Kinase 2 (LRRK2) Pharmacological Inhibition Abates α-Synuclein Gene-induced Neurodegeneration.

Authors:  João P L Daher; Hisham A Abdelmotilib; Xianzhen Hu; Laura A Volpicelli-Daley; Mark S Moehle; Kyle B Fraser; Elie Needle; Yi Chen; Stefanus J Steyn; Paul Galatsis; Warren D Hirst; Andrew B West
Journal:  J Biol Chem       Date:  2015-06-15       Impact factor: 5.157

Review 3.  Viral vector-mediated overexpression of α-synuclein as a progressive model of Parkinson's disease.

Authors:  Ayse Ulusoy; Mickael Decressac; Deniz Kirik; Anders Björklund
Journal:  Prog Brain Res       Date:  2010       Impact factor: 2.453

Review 4.  Lessons from the rotenone model of Parkinson's disease.

Authors:  J Timothy Greenamyre; Jason R Cannon; Robert Drolet; Pier-Giorgio Mastroberardino
Journal:  Trends Pharmacol Sci       Date:  2010-01-22       Impact factor: 14.819

Review 5.  Rab3a and Rab10 are regulators of lysosome exocytosis and plasma membrane repair.

Authors:  Otilia V Vieira
Journal:  Small GTPases       Date:  2016-11-01

6.  Polo-like kinase 2 regulates selective autophagic α-synuclein clearance and suppresses its toxicity in vivo.

Authors:  Abid Oueslati; Bernard L Schneider; Patrick Aebischer; Hilal A Lashuel
Journal:  Proc Natl Acad Sci U S A       Date:  2013-08-27       Impact factor: 11.205

7.  α-Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson's disease.

Authors:  Roberto Di Maio; Paul J Barrett; Eric K Hoffman; Caitlyn W Barrett; Alevtina Zharikov; Anupom Borah; Xiaoping Hu; Jennifer McCoy; Charleen T Chu; Edward A Burton; Teresa G Hastings; J Timothy Greenamyre
Journal:  Sci Transl Med       Date:  2016-06-08       Impact factor: 17.956

8.  Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology.

Authors:  Alexander Zimprich; Saskia Biskup; Petra Leitner; Peter Lichtner; Matthew Farrer; Sarah Lincoln; Jennifer Kachergus; Mary Hulihan; Ryan J Uitti; Donald B Calne; A Jon Stoessl; Ronald F Pfeiffer; Nadja Patenge; Iria Carballo Carbajal; Peter Vieregge; Friedrich Asmus; Bertram Müller-Myhsok; Dennis W Dickson; Thomas Meitinger; Tim M Strom; Zbigniew K Wszolek; Thomas Gasser
Journal:  Neuron       Date:  2004-11-18       Impact factor: 17.173

9.  G2019S-LRRK2 Expression Augments α-Synuclein Sequestration into Inclusions in Neurons.

Authors:  Laura A Volpicelli-Daley; Hisham Abdelmotilib; Zhiyong Liu; Lindsay Stoyka; João Paulo Lima Daher; Austen J Milnerwood; Vivek K Unni; Warren D Hirst; Zhenyu Yue; Hien T Zhao; Kyle Fraser; Richard E Kennedy; Andrew B West
Journal:  J Neurosci       Date:  2016-07-13       Impact factor: 6.167

10.  Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease.

Authors:  Coro Paisán-Ruíz; Shushant Jain; E Whitney Evans; William P Gilks; Javier Simón; Marcel van der Brug; Adolfo López de Munain; Silvia Aparicio; Angel Martínez Gil; Naheed Khan; Janel Johnson; Javier Ruiz Martinez; David Nicholl; Itxaso Martí Carrera; Amets Saénz Pena; Rohan de Silva; Andrew Lees; José Félix Martí-Massó; Jordi Pérez-Tur; Nick W Wood; Andrew B Singleton
Journal:  Neuron       Date:  2004-11-18       Impact factor: 17.173

View more
  123 in total

1.  Mitochondrial clearance and maturation of autophagosomes are compromised in LRRK2 G2019S familial Parkinson's disease patient fibroblasts.

Authors:  Joanna A Korecka; Ria Thomas; Dan P Christensen; Anthony J Hinrich; Eliza J Ferrari; Simon A Levy; Michelle L Hastings; Penelope J Hallett; Ole Isacson
Journal:  Hum Mol Genet       Date:  2019-10-01       Impact factor: 6.150

Review 2.  LRRK2 in Parkinson disease: challenges of clinical trials.

Authors:  Eduardo Tolosa; Miquel Vila; Christine Klein; Olivier Rascol
Journal:  Nat Rev Neurol       Date:  2020-01-24       Impact factor: 42.937

Review 3.  Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs.

Authors:  Delphine Charvin; Rossella Medori; Robert A Hauser; Olivier Rascol
Journal:  Nat Rev Drug Discov       Date:  2018-09-28       Impact factor: 84.694

4.  Trichloroethylene, a ubiquitous environmental contaminant in the risk for Parkinson's disease.

Authors:  Briana R De Miranda; J Timothy Greenamyre
Journal:  Environ Sci Process Impacts       Date:  2020-01-30       Impact factor: 4.238

Review 5.  LRRK2 links genetic and sporadic Parkinson's disease.

Authors:  Jillian H Kluss; Adamantios Mamais; Mark R Cookson
Journal:  Biochem Soc Trans       Date:  2019-03-05       Impact factor: 5.407

6.  Sex Differences in Rotenone Sensitivity Reflect the Male-to-Female Ratio in Human Parkinson's Disease Incidence.

Authors:  Briana R De Miranda; Marco Fazzari; Emily M Rocha; Sandra Castro; J Timothy Greenamyre
Journal:  Toxicol Sci       Date:  2019-07-01       Impact factor: 4.849

Review 7.  Innate and adaptive immune responses in Parkinson's disease.

Authors:  Aubrey M Schonhoff; Gregory P Williams; Zachary D Wallen; David G Standaert; Ashley S Harms
Journal:  Prog Brain Res       Date:  2019-12-05       Impact factor: 2.453

Review 8.  Therapy of Parkinson's Disease Subtypes.

Authors:  Connie Marras; K Ray Chaudhuri; Nataliya Titova; Tiago A Mestre
Journal:  Neurotherapeutics       Date:  2020-10       Impact factor: 7.620

Review 9.  New Frontiers in Parkinson's Disease: From Genetics to the Clinic.

Authors:  Lamya S Shihabuddin; Patrik Brundin; J Timothy Greenamyre; Diane Stephenson; S Pablo Sardi
Journal:  J Neurosci       Date:  2018-10-31       Impact factor: 6.167

10.  The In Situ Structure of Parkinson's Disease-Linked LRRK2.

Authors:  Reika Watanabe; Robert Buschauer; Jan Böhning; Martina Audagnotto; Keren Lasker; Tsan-Wen Lu; Daniela Boassa; Susan Taylor; Elizabeth Villa
Journal:  Cell       Date:  2020-08-11       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.